Use of a Miniaturized Near-Infrared Spectroscopy Device for Type 2 Diabetes Mellitus Screening: Pooled Analysis of the Pilot ANODE01 and ANODE02 Studies
- PMID: 40219802
- PMCID: PMC11993547
- DOI: 10.1177/19322968251331069
Use of a Miniaturized Near-Infrared Spectroscopy Device for Type 2 Diabetes Mellitus Screening: Pooled Analysis of the Pilot ANODE01 and ANODE02 Studies
Abstract
Background: Current diabetes screening methods are complex, inefficient, and inconvenient, requiring resource-intensive blood sampling. With the increasing prevalence of underdiagnosed type 2 diabetes mellitus (T2DM) worldwide, particularly in low-resource settings and underserved populations, affordable and sustainable mass-screening tools are crucial.
Methods: The accuracy and safety of the miniaturized near-infrared (NIR), full-spectrum spectroscopy Glyconics-DS System in detecting T2DM risk status was assessed by pooling data from two independent pilot studies: ANODE01 and ANODE02. Rapid NIR assessments of glycated nail keratin in 60 repeated spectral readings of fingernails from individuals with or without T2DM focused on detecting dichotomized diabetes risk status (glycated hemoglobin [HbA1c] <6.5%) based on chemometric prediction models, clinical specificity/sensitivity, and true/false positive outcomes. An HbA1c point-of-care assay served as an internal control.
Results: Over 12 000 NIR spectral readings were collected in a female-dominant (58.5%), mostly non-smoking (80.0%), diverse cohort of 200 participants (n = 100 with/n = 100 without T2D). The selected chemometrics prediction model on a diagnostic HbA1c cut-off of 6.5% showed a specificity of 92.9% (95% confidence interval [CI] = 88.5-97.4) and a sensitivity of 34.2% (95% CI = 23.4-45.1), with 71.5% concordance. Chemometric predictions were consistent and reproducible with no relevant impact of anthropometric variables, concomitant conditions/medications, smoking status, and number of spectral assessments/nail or hand dominance on NIR assessment. No adverse events or suspected de novo T2D cases were reported.
Conclusions: This pooled analysis of two independent studies demonstrates the clinical feasibility and high specificity of rapid NIR spectral assessment of T2DM risk, with potential for screening, early detection, and sustainable management across health care settings.
Keywords: glycated keratin; hemoglobin; near-infrared spectroscopy; screening; specificity; type 2 diabetes.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PC: Medtronic, Novo Nordisk, Lilly, Sanofi, Abbot, Dexcom, Vertex, Roche, and Insulet; research support: Medtronic, Abbott, Dexcom, and Novo Nordisk. PMP: Consultant; Glyconics Ltd, Altimmune, Speaker’s Bureau; Novartis. JES: Consultant; Glyconics Ltd. DL-P: Employee; Glyconics Ltd. FXCC: AstraZeneca, Abbott, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, and Menarini.
Figures


Similar articles
-
Exploring in-vivo infrared spectroscopy for nail-based diabetes screening.Biomed Opt Express. 2024 Feb 28;15(3):1926-1942. doi: 10.1364/BOE.520102. eCollection 2024 Mar 1. Biomed Opt Express. 2024. PMID: 38495687 Free PMC article.
-
Use of glucometer and fasting blood glucose as screening tools for diabetes mellitus type 2 and glycated haemoglobin as clinical reference in rural community primary care settings of a middle income country.BMC Public Health. 2012 May 14;12:349. doi: 10.1186/1471-2458-12-349. BMC Public Health. 2012. PMID: 22583817 Free PMC article.
-
Analysis of protein glycation in human fingernail clippings with near-infrared (NIR) spectroscopy as an alternative technique for the diagnosis of diabetes mellitus.Clin Chem Lab Med. 2018 Aug 28;56(9):1551-1558. doi: 10.1515/cclm-2018-0239. Clin Chem Lab Med. 2018. PMID: 29750643
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
-
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.Cochrane Database Syst Rev. 2019 Dec 3;12(12):CD008558. doi: 10.1002/14651858.CD008558.pub2. Cochrane Database Syst Rev. 2019. PMID: 31794067 Free PMC article.
References
-
- World Health Organization. WHO factsheets diabetes. Accessed February 14, 2025. https://www.who.int/news-room/fact-sheets/detail/diabetes
-
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2022. https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
-
- Centers for Disease Control and Prevention (CDC). National diabetes statistics report. Estimates of diabetes and its burden in the United States. Published 2023. Accessed February 14, 2025. https://stacks.cdc.gov/view/cdc/148231
LinkOut - more resources
Full Text Sources
Miscellaneous